<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="514">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04399746</url>
  </required_header>
  <id_info>
    <org_study_id>IvAzCol</org_study_id>
    <nct_id>NCT04399746</nct_id>
  </id_info>
  <brief_title>Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19</brief_title>
  <acronym>IvAzCol</acronym>
  <official_title>A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the world faces COVID-19, the search for effective treatments against the disease and its
      complications has turned its gaze to drugs that are classically used in other infectious
      diseases. Some drugs are being examined for the recent evidence on its effects on viral
      replication and inflammation, one is Azithromycin, used to treat a wide variety of bacterial
      infections, Ivermectin, an anti-parasitic drug and the other is Cholecalciferol to increase
      serum concentration of 25-hydroxyvitamin D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to assess the efficacy of Ivermectin-Azithromycin-Cholecalciferol
      combination in COVID-19 in early stages of the disease with outpatient management.

      Enrollment of subject into the trial shall only occur after providing written permission to
      voluntarily participate into the study by signing and dating the informed consent form before
      starting any trial related treatment. 30 cases of COVID-19 will be enrolled into the trial
      with a 3:1 proportion, divided into two groups. First group with confirmed cases of COVID-19
      shall be treated with Ivermectin (6mg once daily in day 0,1,7 and 8) plus Azithromycin (500mg
      once daily for 4 days) plus Cholecalciferol (400 IU twice daily for 30 days) in an outpatient
      regimen. The second group with confirmed cases of COVID-19 who refused treatment were shall
      be allocated as the control group for monitoring.

      Test for virus at day 1 and 14 from beginning of trial drug started for the outpatient
      regimen.

      Clinical symptoms, oxygen saturation and oxygenation index will be monitored every day of the
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Anticipated">June 10, 2020</completion_date>
  <primary_completion_date type="Actual">May 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Relation 3:1 in Combination:Control groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral clearance</measure>
    <time_frame>14 days</time_frame>
    <description>Test for virus at day 1 and 14 from beginning of trial drug started</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms duration</measure>
    <time_frame>14 days</time_frame>
    <description>The duration of symptoms in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>14 days</time_frame>
    <description>oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2/FiO2</measure>
    <time_frame>14 days</time_frame>
    <description>Oxygen Saturation (SpO2)/Fraction of Inspired Oxygen (FiO2) Ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin (6mg once daily in day 0,1,7 and 8) plus Azithromycin (500mg once daily for 4 days) plus Cholecalciferol (400 IU twice daily for 30 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>6mg once daily in day 0,1,7 and 8</description>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>500mg once daily for 4 days</description>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>400 IU twice daily for 30 days</description>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed infection of SARS-CoV2 virus

          -  Mild COVID-19

          -  Symptoms of respiratory illness

          -  Cough

          -  Fever (T &gt;38 Â°C)

        Exclusion Criteria:

          -  Allergy to any of the drugs treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guadalupe Espitia, MD, PhD</last_name>
    <phone>01 5554471424</phone>
    <phone_ext>13272</phone_ext>
    <email>lupitaespitia@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Outpatient treatment</name>
      <address>
        <city>Mexico City</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guadalupe Espitia, MD, PhD</last_name>
      <phone>01 5554471424</phone>
      <phone_ext>13272</phone_ext>
      <email>lupitaespitia@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado</investigator_affiliation>
    <investigator_full_name>Guadalupe Espitia Hernandez, MD, PhD</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

